Cochrane Review Group
Haematology
78 systematic reviews in Haematology ask 987 questions. 25.9% have no studies to answer them, 21% rest on very low certainty evidence and 21.6% reach moderate or high certainty.
Reviews
78
Questions
987
current versions
No studies
25.9%
Moderate or high
21.6%
No studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | RR 1 [0.27, 3.7] | 3 studies · 451 participants | Very low |
Intervention NR Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 1 study · 84 participants | Very low |
Intervention NR Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 3 studies · 431 participants | Very low |
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 1 study · 84 participants | Very low |
Intervention NR Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory drug maintenance therapy vs placebo/observation Treatment discontinuation · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 0.71 [0.47, 1.05] | 2 studies · 400 participants | Very low |
Anti‐CD52 mAb maintenance therapy vs observation Overall survival – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 78
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support
CochraneSoF table
14 questions
Maintenance therapy for chronic lymphocytic leukaemia
CochraneSoF table
21 questions
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
CochraneSoF table
7 questions
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults
CochraneSoF table
7 questions
Convalescent plasma for people with COVID‐19: a living systematic review
CochraneSoF table
32 questions
Remdesivir for the treatment of COVID‐19
CochraneSoF table
13 questions
Antiplatelet agents for the treatment of adults with COVID‐19
CochraneSoF table
14 questions
Hyperimmune immunoglobulin for people with COVID‐19
CochraneSoF table
14 questions
Early versus late tracheostomy in critically ill COVID‐19 patients
CochraneSoF table
9 questions
Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis
CochraneSoF table
14 questions
SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19
CochraneSoF table
38 questions
Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence
CochraneSoF table
24 questions
Ivermectin for preventing and treating COVID‐19
CochraneSoF table
16 questions
Janus kinase inhibitors for the treatment of COVID‐19
CochraneSoF table
8 questions
Fluvoxamine for the treatment of COVID‐19
CochraneSoF table
7 questions
Disease‐modifying treatments for primary autoimmune haemolytic anaemia
CochraneSoF table
7 questions
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
CochraneSoF table
7 questions
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
CochraneSoF table
54 questions
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
CochraneSoF table
34 questions
Antibiotics for the treatment of COVID‐19
CochraneSoF table
15 questions
Vitamin D supplementation for the treatment of COVID‐19: a living systematic review
CochraneSoF table
6 questions
Colchicine for the treatment of COVID‐19
CochraneSoF table
13 questions
Interim PET‐results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta‐analysis of prognostic factor studies
CochraneSoF table
5 questions
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
CochraneSoF table
14 questions
Aerobic physical exercise for adult patients with haematological malignancies
CochraneSoF table
7 questions